JP2024503637A5 - - Google Patents
Info
- Publication number
- JP2024503637A5 JP2024503637A5 JP2023541264A JP2023541264A JP2024503637A5 JP 2024503637 A5 JP2024503637 A5 JP 2024503637A5 JP 2023541264 A JP2023541264 A JP 2023541264A JP 2023541264 A JP2023541264 A JP 2023541264A JP 2024503637 A5 JP2024503637 A5 JP 2024503637A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- group
- hydrate
- amino acid
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163134704P | 2021-01-07 | 2021-01-07 | |
| US63/134,704 | 2021-01-07 | ||
| PCT/EP2022/050280 WO2022148843A1 (en) | 2021-01-07 | 2022-01-07 | Compounds comprising a fibroblast activation protein ligand and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024503637A JP2024503637A (ja) | 2024-01-26 |
| JP2024503637A5 true JP2024503637A5 (https=) | 2025-11-12 |
Family
ID=80050672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023541264A Pending JP2024503637A (ja) | 2021-01-07 | 2022-01-07 | 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230212549A1 (https=) |
| EP (1) | EP4274835A1 (https=) |
| JP (1) | JP2024503637A (https=) |
| KR (1) | KR20230129261A (https=) |
| CN (1) | CN116940585A (https=) |
| AU (1) | AU2022205523A1 (https=) |
| CA (1) | CA3206863A1 (https=) |
| CL (5) | CL2023001991A1 (https=) |
| IL (1) | IL303925A (https=) |
| MX (1) | MX2023007869A (https=) |
| WO (1) | WO2022148843A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220072092A1 (en) * | 2016-06-24 | 2022-03-10 | University Of Iowa Research Foundation | Compositions and methods of treating melanoma |
| FI3997103T3 (fi) | 2019-07-08 | 2025-02-03 | 3B Pharmaceuticals Gmbh | Fibroblastien aktivaatioproteiinin ligandia käsittäviä yhdisteitä ja niiden käyttö |
| EP4475900A1 (en) | 2022-02-09 | 2024-12-18 | Novartis AG | Pharmaceutical compositions comprising a 225-actinium-labelled complex and a bismuth sequestering agent |
| EP4692105A1 (en) * | 2023-03-27 | 2026-02-11 | Bivision Pharmaceuticals, Inc | Cyclic polypeptide compound and use thereof |
| WO2024198836A1 (zh) * | 2023-03-27 | 2024-10-03 | 晶核生物医药科技(南京)有限公司 | 环状多肽类化合物及其应用 |
| WO2024198838A1 (zh) * | 2023-03-27 | 2024-10-03 | 晶核生物医药科技(南京)有限公司 | 环状多肽类化合物及其应用 |
| CN118930606A (zh) * | 2023-05-11 | 2024-11-12 | 成都纽瑞特医疗科技股份有限公司 | 靶向成纤维细胞活化蛋白的多肽放射性核素配合物及其应用 |
| KR20260026051A (ko) * | 2023-06-14 | 2026-02-25 | 마리아나 온콜로지 인크. | Dll3 표적화 펩티드 및 이의 구성체 |
| CN121712787A (zh) * | 2023-06-14 | 2026-03-20 | 马里亚纳肿瘤学公司 | 靶向dll3的肽及其构建体 |
| CN121712788A (zh) * | 2023-06-14 | 2026-03-20 | 马里亚纳肿瘤学公司 | 靶向dll3的肽及其构建体 |
| WO2025011611A1 (zh) * | 2023-07-11 | 2025-01-16 | 江苏恒瑞医药股份有限公司 | 一种成纤维细胞活化蛋白配体及其用途 |
| WO2025082283A1 (zh) * | 2023-10-16 | 2025-04-24 | 四川科伦博泰生物医药股份有限公司 | 环肽结构的配体化合物及其核素标记物、药物组合物及应用 |
| WO2025117586A1 (en) * | 2023-11-27 | 2025-06-05 | Mariana Oncology Inc. | Dll3 targeting peptides and constructs thereof |
| US20250186630A1 (en) * | 2023-12-12 | 2025-06-12 | Viewpoint Molecular Targeting, Inc. | Fibroblast activation protein targeting peptides |
| WO2025163556A1 (en) | 2024-02-01 | 2025-08-07 | Novartis Ag | Methods for treating cancer |
| TW202600606A (zh) * | 2024-02-21 | 2026-01-01 | 美商雅博得樂醫療公司 | 抗體連接子結合物 |
| WO2025179168A1 (en) * | 2024-02-22 | 2025-08-28 | Mariana Oncology Inc. | Synthesis of dll3-binding peptides |
| WO2025252221A1 (zh) * | 2024-06-07 | 2025-12-11 | 中国科学院上海药物研究所 | 一类靶向肿瘤相关成纤维细胞激活蛋白的糖肽、放射性核素标记物及其应用 |
| CN121045338A (zh) * | 2025-11-05 | 2025-12-02 | 原子高科股份有限公司 | 一种靶向caix的环肽及其制备方法与应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4885363A (en) | 1987-04-24 | 1989-12-05 | E. R. Squibb & Sons, Inc. | 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs |
| US5021556A (en) | 1987-07-22 | 1991-06-04 | Neorx Corporation | Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides |
| US5075099A (en) | 1988-05-31 | 1991-12-24 | Neorx Corporation | Metal radionuclide chelating compounds for improved chelation kinetics |
| US5364613A (en) | 1989-04-07 | 1994-11-15 | Sieving Paul F | Polychelants containing macrocyclic chelant moieties |
| US5367080A (en) | 1990-11-08 | 1994-11-22 | Sterling Winthrop Inc. | Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods |
| US5886142A (en) | 1997-05-20 | 1999-03-23 | Thomas Jefferson University | Radiolabeled thrombus imaging agents |
| ATE357509T1 (de) | 1997-09-29 | 2007-04-15 | Point Therapeutics Inc | Stimulierung von hämatopoietischen zellen im vitro |
| EP0953639A1 (en) | 1998-04-30 | 1999-11-03 | Boehringer Ingelheim International GmbH | FAPalpha-specific antibody with improved producibility |
| US6890904B1 (en) | 1999-05-25 | 2005-05-10 | Point Therapeutics, Inc. | Anti-tumor agents |
| EP1268550A2 (en) | 2000-03-17 | 2003-01-02 | Boehringer Ingelheim Pharma KG | Human fap-alpha-specific antibodies |
| US7374898B2 (en) | 2004-10-12 | 2008-05-20 | The Research Foundation Of State University Of New York | Peptide inhibitors against seprase |
| US7399869B2 (en) | 2005-05-19 | 2008-07-15 | Genentech, Inc. | Fibroblast activation protein inhibitor compounds and methods |
| US8933201B2 (en) | 2006-06-07 | 2015-01-13 | The Board Of Regents Of The University Of Oklahoma | Substrates and inhibitors of antiplasmin cleaving enzyme and fibroblast activation protein and methods of use |
| WO2008116054A1 (en) | 2007-03-20 | 2008-09-25 | Trustees Of Tufts College | Inhibitors of fibroblast activation protein, and methods of use thereof |
| WO2010036814A1 (en) | 2008-09-25 | 2010-04-01 | Molecular Insight Pharmaceuticals, Inc. | Selective seprase inhibitors |
| CA2776037A1 (en) | 2009-10-02 | 2011-04-07 | Ludwig Institute For Cancer Research Ltd | Anti-fibroblast activation protein antibodies and methods and uses thereof |
| CA2806021C (en) | 2010-08-13 | 2019-05-21 | Roche Glycart Ag | Anti-fap antibodies and methods of use |
| WO2013107820A1 (en) | 2012-01-17 | 2013-07-25 | Universiteit Antwerpen | Novel fap inhibitors |
| UA118028C2 (uk) | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування |
| GB201402006D0 (en) | 2014-02-06 | 2014-03-26 | Oncomatryx Biopharma S L | Antibody-drug conjugates and immunotoxins |
| WO2016146174A1 (en) * | 2015-03-17 | 2016-09-22 | Biontech Ag | Compositions and methods for diagnosis and treatment of cancer |
| CN109689115A (zh) | 2016-06-10 | 2019-04-26 | 拜耳制药股份公司 | 放射性药物配合物 |
| JP2018035137A (ja) | 2016-07-13 | 2018-03-08 | マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ | 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用 |
| EA202090776A1 (ru) * | 2017-10-23 | 2020-07-27 | Дзе Джонс Хопкинс Юниверсити | Визуализирующие и радиотерапевтические агенты, нацеленные на фибробласт-активирующий белок-альфа (fapalpha) |
| EP3763726A1 (en) * | 2019-07-08 | 2021-01-13 | 3B Pharmaceuticals GmbH | Compounds comprising a fibroblast activation protein ligand and use thereof |
-
2022
- 2022-01-07 IL IL303925A patent/IL303925A/en unknown
- 2022-01-07 MX MX2023007869A patent/MX2023007869A/es unknown
- 2022-01-07 CA CA3206863A patent/CA3206863A1/en active Pending
- 2022-01-07 EP EP22700892.7A patent/EP4274835A1/en active Pending
- 2022-01-07 WO PCT/EP2022/050280 patent/WO2022148843A1/en not_active Ceased
- 2022-01-07 CN CN202280019456.5A patent/CN116940585A/zh active Pending
- 2022-01-07 KR KR1020237026404A patent/KR20230129261A/ko active Pending
- 2022-01-07 US US17/571,067 patent/US20230212549A1/en active Pending
- 2022-01-07 AU AU2022205523A patent/AU2022205523A1/en active Pending
- 2022-01-07 JP JP2023541264A patent/JP2024503637A/ja active Pending
-
2023
- 2023-07-06 CL CL2023001991A patent/CL2023001991A1/es unknown
-
2024
- 2024-05-28 CL CL2024001600A patent/CL2024001600A1/es unknown
- 2024-05-28 CL CL2024001597A patent/CL2024001597A1/es unknown
- 2024-05-28 CL CL2024001599A patent/CL2024001599A1/es unknown
- 2024-05-28 CL CL2024001596A patent/CL2024001596A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024503637A5 (https=) | ||
| ES2615805T3 (es) | Conjugados de antagonista de péptido análogo de la bombesina | |
| US8414864B2 (en) | Gastrin releasing peptide compounds | |
| CN103533963B (zh) | 用通过nota络合的[18]氟化铝标记的her2结合肽 | |
| CN103402550B (zh) | 用含有18f的有机硅化合物标记的her2结合肽 | |
| JP7502801B2 (ja) | ガストリン放出ペプチド受容体（ｇｒｐｒ）のインビボイメージングおよびｇｒｐｒ関連障害の治療のための放射性標識ボンベシン由来化合物 | |
| KR102718575B1 (ko) | 진단 및 치료를 위한 개선된 약동학 및 콜레시스토키닌-2 수용체(cck2r) 표적화 | |
| JP2022537946A (ja) | 化合物及びそれらの使用方法 | |
| JP2025106360A (ja) | 癌のイメージングおよび治療のための修飾されたｇｒｐｒアンタゴニストペプチド | |
| TW202541853A (zh) | 增濃且安定之放射配體治療調製劑及包含彼之醫藥組成物 | |
| US20120178906A1 (en) | Chelation of metals to thiol groups using in situ reduction of disulfide-containing compounds by phosphines | |
| TW202241926A (zh) | 用於診斷及治療之改良的膽囊收縮素-2受體(cck2r)標靶 | |
| TW202231655A (zh) | 用於診斷及治療之改良的膽囊收縮素-2受體(cck2r)標靶 | |
| EP4631959A2 (en) | Novel minigastrin-derived cholecystokinin 2 receptor binding molecules for imaging and targeted radiotherapy | |
| CA3210561A1 (en) | Improved cholecystokinin-2 receptor (cck2r) targeting for diagnosis and therapy | |
| HK1191244A (en) | Her2 binding peptides labelled with a 18f - containing organosilicon compound | |
| HK1193987A (en) | Her2 binding peptides labeled with aluminium-[18] fluoride complexed by nota |